MDMA Therapy Training Program Update: February 2022

The 2022 training schedule has been posted on the training website, including options for a blended (online/in person) training format and an entirely virtual training format.  

Blended format cohorts:

  • April 3-9, North Carolina 
  • May 22-27, Colorado 
  • June 12 – 18, New York 
  • September 11-17, North Carolina 
  • September 25-30, Colorado 
  • October 9-14, New York 

Virtual cohorts (subject to change): 

  • Fall 2022 Virtual Cohort (October-January)

Application Information  

The training application will remain open for future cohorts. Applications will be reviewed during an admissions and screening process for upcoming cohorts. (Apply Here)   

Previously submitted applications will remain on file and will be reviewed for upcoming training opportunities.  

For eligible applicants interested in applying for a MAPS Health Equity Scholarship, please find more information and the link to the application at (Scholarship Page & Application). 

Adherence Rating 

The Adherence Rater Program is completing its sixth Adherence Rater Training this month. Adherence Raters are mental health professionals who review session videos from the MAPS-sponsored clinical trials to ensure adherence to the treatment manual and support ongoing therapist oversight. Over the past year, our small-but-mighty team of 48 Adherence Raters has reviewed and rated over a thousand hours of session footage in five different languages for the MAPS-sponsored trials! 

Supervision and Consultation 

The Supervision Program continues to provide oversight and support to therapists working on the MAPS-sponsored and Investigator-Initiated trials of MDMA-Assisted Therapy for PTSD. Over the past year, Supervisors have conducted nearly 150 Supervision Meetings with therapists working on the MAPS-sponsored trials.   

Planning efforts are underway for our Supervision Program which will support the many MAPS trained MDMA-assisted therapy practitioners that hope to offer this treatment modality in a post FDA approval world.  Planning efforts include the development of upcoming Supervisor Training events.    

Supervision and Consultation are provided to MAPS-sponsored and Investigator-Initiated Trials all over the world.  Starting this month, Consultation provided by MAPS Certified Supervisors is also supporting the use of MDMA-assisted therapy in Switzerland in a clinical setting, where Compassionate Use guidelines allow for the use of psychedelic therapies.